Dankook University is joining hands with LegoChem Biosciences, Inc., a KOSDAQ listed company, to open the ‘DKU-LCB Innovative Anti-Cancer Drug Research Center’ and to conduct joint studies on next-generation anticancer drugs to fight mutant cancer.
On July 21, DKU President Soo-bok Kim and LegoChem Biosciences CEO Yong-zu Kim signed an MOU at the Industry-Academia Partnership Hall on Dankook’s Cheonan Campus. The agreement includes details on the two parties collaborating in △discovering and developing anticancer new drugs, △commissioned research and mutual technology guidance, △joint development and operations of a talent cultivation program, and △joint use of test analysis facilities and equipment to expedite the discovery of new anticancer drugs.
According to the agreement, the ‘DKU-LCB Innovative Anti-Cancer Drug Research Lab (Director Jeong-hee Cho)’ will be set up at the Cheonan Campus Industry-Academia Partnership Hall where the cancer research of Professor Jeong-hee Cho’s (Department of Medical Biotechnology) team will come together with LegoChem Biosciences’ antibody drug conjugate (ADC) technology for joint research on next-generation new drugs to fight cancer with gene mutations.
